Literature DB >> 18621920

Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.

Brian J Van Lenten1, Alan C Wagner, Chun-Ling Jung, Piotr Ruchala, Alan J Waring, Robert I Lehrer, Andrew D Watson, Susan Hama, Mohamad Navab, G M Anantharamaiah, Alan M Fogelman.   

Abstract

4F is an anti-inflammatory, apolipoprotein A-I (apoA-I)-mimetic peptide that is active in vivo at nanomolar concentrations in the presence of a large molar excess of apoA-I. Physiologic concentrations ( approximately 35 microM) of human apoA-I did not inhibit the production of LDL-induced monocyte chemotactic activity by human aortic endothelial cell cultures, but adding nanomolar concentrations of 4F in the presence of approximately 35 microM apoA-I significantly reduced this inflammatory response. We analyzed lipid binding by surface plasmon resonance. The anti-inflammatory 4F peptide bound oxidized lipids with much higher affinity than did apoA-I. Initially, we examined the binding of PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphatidylcholine) and observed that its oxidized products bound 4F with an affinity that was approximately 4-6 orders of magnitude higher than that of apoA-I. This high binding affinity was confirmed in studies with defined lipids and phospholipids. 3F-2 and 3F(14) are also amphipathic alpha-helical octadecapeptides, but 3F-2 inhibits atherosclerosis in mice and 3F(14) does not. Like 4F, 3F-2 also bound oxidized phospholipids with very high affinity, whereas 3F(14) resembled apoA-I. The extraordinary ability of 4F to bind pro-inflammatory oxidized lipids probably accounts for its remarkable anti-inflammatory properties.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18621920      PMCID: PMC2563211          DOI: 10.1194/jlr.M800075-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  40 in total

1.  Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.

Authors:  G Datta; M Chaddha; S Hama; M Navab; A M Fogelman; D W Garber; V K Mishra; R M Epand; R F Epand; S Lund-Katz; M C Phillips; J P Segrest; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2001-07       Impact factor: 5.922

2.  Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.

Authors:  Mohamad Navab; G M Anantharamaiah; Susan Hama; David W Garber; Manjula Chaddha; Greg Hough; Roger Lallone; Alan M Fogelman
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

3.  Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta.

Authors:  Ganesamoorthy Subbanagounder; Jason W Wong; Hans Lee; Kym F Faull; Elizabeth Miller; Joseph L Witztum; Judith A Berliner
Journal:  J Biol Chem       Date:  2001-12-19       Impact factor: 5.157

4.  A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis.

Authors:  D W Garber; G Datta; M Chaddha; M N Palgunachari; S Y Hama; M Navab; A M Fogelman; J P Segrest; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2001-04       Impact factor: 5.922

5.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.

Authors:  M Navab; S Y Hama; G M Anantharamaiah; K Hassan; G P Hough; A D Watson; S T Reddy; A Sevanian; G C Fonarow; A M Fogelman
Journal:  J Lipid Res       Date:  2000-09       Impact factor: 5.922

6.  L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease.

Authors:  Jingsong Ou; Zhijun Ou; Deron W Jones; Sandra Holzhauer; Ossama A Hatoum; Allan W Ackerman; Dorothee W Weihrauch; David D Gutterman; Karen Guice; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  Circulation       Date:  2003-05-05       Impact factor: 29.690

7.  An apolipoprotein AI mimetic peptide: membrane interactions and the role of cholesterol.

Authors:  Richard M Epand; Raquel F Epand; Brian G Sayer; Giuseppe Melacini; Mayakonda N Palgulachari; Jere P Segrest; G M Anantharamaiah
Journal:  Biochemistry       Date:  2004-05-04       Impact factor: 3.162

8.  A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions.

Authors:  Eugene A Podrez; Eugenia Poliakov; Zhongzhou Shen; Renliang Zhang; Yijun Deng; Mingjiang Sun; Paula J Finton; Lian Shan; Maria Febbraio; David P Hajjar; Roy L Silverstein; Henry F Hoff; Robert G Salomon; Stanley L Hazen
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

9.  L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells.

Authors:  Zhijun Ou; Jingsong Ou; Allan W Ackerman; Keith T Oldham; Kirkwood A Pritchard
Journal:  Circulation       Date:  2003-03-25       Impact factor: 29.690

10.  Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide.

Authors:  Brian J Van Lenten; Alan C Wagner; G M Anantharamaiah; David W Garber; Michael C Fishbein; Lopa Adhikary; Debi P Nayak; Susan Hama; Mohamad Navab; Alan M Fogelman
Journal:  Circulation       Date:  2002-08-27       Impact factor: 29.690

View more
  102 in total

1.  D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice.

Authors:  Mohamad Navab; Srinivasa T Reddy; G M Anantharamaiah; Greg Hough; Georgette M Buga; Jan Danciger; Alan M Fogelman
Journal:  J Lipid Res       Date:  2011-12-13       Impact factor: 5.922

2.  Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice.

Authors:  Shaila P Handattu; Geeta Datta; Richard M Epand; Raquel F Epand; Mayakonda N Palgunachari; Vinod K Mishra; Candyce E Monroe; Tamara D Keenum; Manjula Chaddha; G M Anantharamaiah; David W Garber
Journal:  J Lipid Res       Date:  2010-09-14       Impact factor: 5.922

3.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

4.  L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice.

Authors:  Satoshi Imaizumi; Victor Grijalva; Mohamad Navab; Brian J Van Lenten; Alan C Wagner; G M Anantharamiah; Alan M Fogelman; Srinivasa T Reddy
Journal:  Drug Metab Lett       Date:  2010-08

Review 5.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

6.  L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.

Authors:  Feng Gao; Sergio X Vasquez; Feng Su; Svetlana Roberts; Neha Shah; Victor Grijalva; Satoshi Imaizumi; Arnab Chattopadhyay; Ekambaram Ganapathy; David Meriwether; Brad Johnston; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Integr Biol (Camb)       Date:  2011-02-01       Impact factor: 2.192

7.  Molecular targets for diabetes mellitus-associated erectile dysfunction.

Authors:  Elizabeth Yohannes; Jinsook Chang; Moses T Tar; Kelvin P Davies; Mark R Chance
Journal:  Mol Cell Proteomics       Date:  2009-12-10       Impact factor: 5.911

Review 8.  The role of dysfunctional HDL in atherosclerosis.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

9.  Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).

Authors:  C Roger White; Geeta Datta; Paulina Mochon; Zhenghao Zhang; Ollie Kelly; Christine Curcio; Dale Parks; Mayakonda Palgunachari; Shaila Handattu; Himanshu Gupta; David W Garber; G M Anantharamaiah
Journal:  Vasc Dis Prev       Date:  2009-01-01

10.  The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage.

Authors:  C Roger White; Geeta Datta; Landon Wilson; Mayakonda N Palgunachari; G M Anantharamaiah
Journal:  Chem Phys Lipids       Date:  2019-01-29       Impact factor: 3.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.